
Opinion|Videos|October 13, 2023
Updates in the Management of Lower-Risk MDS
Author(s)Amer Zeidan, MBBS
Amer Zeidan, MBBS, MHS, reviews recent luspatercept and imetelstat data from the COMMANDS and IMerge clinical trials in lower-risk myelodysplastic syndrome.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
2
Early Relapse Guides Use of CAR T vs Other Options in LBCL
3
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5













































